Company Profile

EAvid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.

Employees

Sector

Pharmaceuticals

More about the company

05-18	Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer	CI
05-11	Avid Bioservices, Inc. Appoints Kerri McCullough Wood as Chief Commercial Officer	CI
02-24	Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California	CI
01-15	Avid Bioservices Appoints Rich Mcavoy as Chief Business Officer	CI
11-10	Avid Bioservices Appoints Dave Stewart as Chief Technology and Transformation Officer	CI
15/09/25	Avid Bioservices Announces CEO Changes	CI
06/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Biotechnology Select Industry Index	CI
06/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Global BMI Index	CI
06/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P TMI Index	CI
05/02/25	Avid Bioservices, Inc. Announces Cessation of Board and Committee Members	CI
04/02/25	Funds managed by GHO Capital Partners LLP and Ampersand Management LLC completed the acquisition of Avid Bioservices, Inc. from a group of shareholders.	CI
04/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from NASDAQ Composite Index	CI
30/01/25	Avid Shareholders Approve Acquisition by GHO, Ampersand	MT

04/12/24	Stephens Downgrades Avid Bioservices to Equalweight, Price Target is $12.50	MT
07/11/24	RBC Capital Downgrades Avid Bioservices to Sector Perform From Outperform, Adjusts PT to $12.50 From $12	MT
07/11/24	RBC Capital Downgrades Avid Bioservices to Sector Perform, Price Target is $12.50	MT
10/09/24	Avid Bioservices Shares Jump as RBC Boosts Price Target After Bookings Beat	MT
10/09/24	RBC Raises Price Target on Avid Bioservices to $12 From $8, Maintains Outperform Rating	MT

10/02/25	Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience	AQ
06/02/25	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	AQ
05/02/25	Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger	GL
05/02/25	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	GL
05/02/25	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	AQ

Manager	Title	Age	Since
Kenneth Bilenberg CEO	Chief Executive Officer	-	14/09/2025
Richard McAvoy DFI	Director of Finance/CFO	-	31/05/2026
David Stewart CTO	Chief Tech/Sci/R&D Officer	-	31/10/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEREGRINE PHARMACEUTICALS	-2.83%	+7.69%	-	-	799M
ELI LILLY AND COMPANY	+0.35%	+1.36%	+45.38%	+140.47%	1,280B
JOHNSON & JOHNSON	-0.13%	+1.48%	+44.67%	+90.43%	675B
ABBVIE INC.	+0.37%	+0.05%	+31.00%	+112.84%	521B
ROCHE HOLDING AG	+0.02%	+1.52%	+39.21%	+69.76%	386B
MERCK & CO., INC.	-0.59%	-2.11%	+61.83%	+45.16%	363B
NOVARTIS AG	-1.29%	-1.13%	+27.54%	+58.29%	301B
ASTRAZENECA PLC	+0.09%	-0.91%	+3.19%	+37.72%	286B
AMGEN INC.	+0.62%	-2.17%	+38.31%	+75.12%	253B
GILEAD SCIENCES, INC.	-0.67%	-2.72%	+38.49%	+123.56%	211B
Average	-0.25%	-0.51%	+36.62%	+83.71%	475B
Weighted average by Cap.	+0.47%	+0.20%	+39.52%	+97.37%

Peregrine Pharmaceuticals Share Price Nasdaq

Stocks

US7136613046

Pharmaceuticals

Latest news: Peregrine Pharmaceuticals

Analysts' recommendations: Peregrine Pharmaceuticals

Press Releases: Peregrine Pharmaceuticals

News in other languages: Peregrine Pharmaceuticals

Quotes and Performance

Managers and Directors: Peregrine Pharmaceuticals

Biopharmaceuticals

Company Profile